Colton Strong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Colton Strong has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Jerry Leung
Department of Biochemistry and Molecular Biology University of British Columbia Vancouver British Columbia Canada
4 shared publications Emma Kang
Department of Biochemistry and Molecular Biology University of British Columbia Vancouver British Columbia Canada
3 shared publications- Christian J. Kastrup
Department of Biochemistry and Molecular Biology University of British Columbia Vancouver British Columbia Canada
2 shared publications - Eric Jan
Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, Canada
2 shared publications - Katherine E. Badior
Versiti Blood Research Institute, Milwaukee, WI
2 shared publications - Madelaine K. Robertson
Dalhousie University
2 shared publications
Latest Publications
- Open Access
- 27 September 2026
- Published by Wiley in Advanced Materials
- Vol. 38 (63) , e75174
Increasing Lipid Nanoparticle mRNA Copy Number Improves Transfection Potency
Lipid nanoparticles (LNPs) are the leading platform for delivery of RNA‐based therapeutics. There is considerable interest in optimizing the transfection potency of these systems. Standard formulation protocols involve mixing lipids in ethanol with a buffer containing mRNA at pH 4, followed by dialysis against a pH 7.4 saline buffer to remove ethanol and raise the pH. The dialysis process results in fusion of mRNA‐lipid complexes and small vesicles formed at pH 4, driven by two processes: Conversion of the ionizable lipid from the positively charged bilayer form to the neutral oil form and fusion stimulated by higher ionic strengths. Here we explored the consequences of a two‐step dialysis process involving formulating at pH 4, 25 mM NaOAc, and then inducing fusion at pH 4 by dialyzing against a higher ionic strength buffer while maintaining the ethanol concentration at 25% (v/v). This was followed by dialysis against PBS to raise the pH. We show that the two‐step protocol results in increased mRNA loading per LNP, a decreased proportion of “empties” as compared to the standard process, and improved transfection potencies in vitro and in vivo when compared to LNP mRNA formed from the traditional one‐step buffer exchange process.
- 27 September 2026
- Published by Wiley in Advanced Materials
- Vol. 38 (63) , e75174
Open AccessIncreasing Lipid Nanoparticle mRNA Copy Number Improves Transfection Potency
Lipid nanoparticles (LNPs) are the leading platform for delivery of RNA‐based therapeutics. There is considerable interest in optimizing the transfection potency of these systems. Standard formulation protocols involve mixing lipids in ethanol with a buffer containing mRNA at pH 4, followed by dialysis against a pH 7.4 saline buffer to remove ethanol and raise the pH. The dialysis process results in fusion of mRNA‐lipid complexes and small vesicles formed at pH 4, driven by two processes: Conversion of the ionizable lipid from the positively charged bilayer form to the neutral oil form and fusion stimulated by higher ionic strengths. Here we explored the consequences of a two‐step dialysis process involving formulating at pH 4, 25 mM NaOAc, and then inducing fusion at pH 4 by dialyzing against a higher ionic strength buffer while maintaining the ethanol concentration at 25% (v/v). This was followed by dialysis against PBS to raise the pH. We show that the two‐step protocol results in increased mRNA loading per LNP, a decreased proportion of “empties” as compared to the standard process, and improved transfection potencies in vitro and in vivo when compared to LNP mRNA formed from the traditional one‐step buffer exchange process.
- Top Cited PapersOpen Access
- 3 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-12
Liposomal lipid nanoparticles for extrahepatic delivery of mRNA
Long-circulating, transfection-competent lipid nanoparticle (LNP)-mRNA delivery systems are critical for achieving efficient transfection in extrahepatic tissues. Here we investigate the properties of LNP mRNA systems containing high proportions of bilayer forming lipids, using equimolar egg sphingomyelin and cholesterol as the bilayer-forming components. We show that LNP mRNA systems prepared at bilayer lipid to ionizable lipid molar ratios of 4-0.67 exhibit high mRNA encapsulation efficiencies (90–100%) and excellent transfection potencies in vitro. Systems with bilayer lipid to ionizable lipid molar ratios equating to 4 exhibit a liposomal morphology with a solid core suspended in an aqueous interior surrounded by a lipid bilayer. These liposomal LNPs exhibit longer circulation lifetimes than LNP systems with Onpattro-like lipid compositions and have enhanced extrahepatic transfection properties. The prolonged blood circulation lifetime is attributed to reduced plasma protein adsorption. The transfection competency of liposomal LNP systems is attributed to export of the solid core containing mRNA from the LNP as the endosomal pH is lowered.
- 3 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-12
Top Cited PapersOpen AccessLiposomal lipid nanoparticles for extrahepatic delivery of mRNA
Long-circulating, transfection-competent lipid nanoparticle (LNP)-mRNA delivery systems are critical for achieving efficient transfection in extrahepatic tissues. Here we investigate the properties of LNP mRNA systems containing high proportions of bilayer forming lipids, using equimolar egg sphingomyelin and cholesterol as the bilayer-forming components. We show that LNP mRNA systems prepared at bilayer lipid to ionizable lipid molar ratios of 4-0.67 exhibit high mRNA encapsulation efficiencies (90–100%) and excellent transfection potencies in vitro. Systems with bilayer lipid to ionizable lipid molar ratios equating to 4 exhibit a liposomal morphology with a solid core suspended in an aqueous interior surrounded by a lipid bilayer. These liposomal LNPs exhibit longer circulation lifetimes than LNP systems with Onpattro-like lipid compositions and have enhanced extrahepatic transfection properties. The prolonged blood circulation lifetime is attributed to reduced plasma protein adsorption. The transfection competency of liposomal LNP systems is attributed to export of the solid core containing mRNA from the LNP as the endosomal pH is lowered.
- 21 November 2024
- Published by American Society of Hematology in Blood
- Vol. 144 (21) , 2223-2236
Genetic engineering of transfusable platelets with mRNA-lipid nanoparticles is compatible with blood banking practices
Platelets contribute to a variety of physiological processes, including inflammation, sepsis, and cancer. However, because of their primary role in hemostasis, platelet transfusions are largely restricted to managing thrombocytopenia and bleeding. One way to expand the utility of platelet transfusions would be to genetically engineer donor platelets with new or enhanced functions. We have previously shown that lipid nanoparticles containing mRNA (mRNA-LNP) can be used to genetically modify authentic platelets in a nonclinical crystalloid solution. Currently, platelets collected for transfusion are stored in plasma or in plasma supplemented with platelet additive solution (PAS) at supraphysiological concentrations at room temperature, or at 4°C if intended for use in acute hemorrhage. Here, we describe a new plasma-optimized mRNA-LNP for transfecting platelets directly in plasma and plasma supplemented with PAS that is scalable to physiological and supraphysiological platelet concentrations. Transfecting platelets in clinical solutions with mRNA-LNP does not affect aspects of in vitro physiology, and transfected platelets are storable. The compatibility of this transfection system with current clinical practices could enable future mRNA-LNP–based platelet products and cell therapies.
- 21 November 2024
- Published by American Society of Hematology in Blood
- Vol. 144 (21) , 2223-2236
Genetic engineering of transfusable platelets with mRNA-lipid nanoparticles is compatible with blood banking practices
Platelets contribute to a variety of physiological processes, including inflammation, sepsis, and cancer. However, because of their primary role in hemostasis, platelet transfusions are largely restricted to managing thrombocytopenia and bleeding. One way to expand the utility of platelet transfusions would be to genetically engineer donor platelets with new or enhanced functions. We have previously shown that lipid nanoparticles containing mRNA (mRNA-LNP) can be used to genetically modify authentic platelets in a nonclinical crystalloid solution. Currently, platelets collected for transfusion are stored in plasma or in plasma supplemented with platelet additive solution (PAS) at supraphysiological concentrations at room temperature, or at 4°C if intended for use in acute hemorrhage. Here, we describe a new plasma-optimized mRNA-LNP for transfecting platelets directly in plasma and plasma supplemented with PAS that is scalable to physiological and supraphysiological platelet concentrations. Transfecting platelets in clinical solutions with mRNA-LNP does not affect aspects of in vitro physiology, and transfected platelets are storable. The compatibility of this transfection system with current clinical practices could enable future mRNA-LNP–based platelet products and cell therapies.
- Open Access
- 1 December 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (48) , eadi0508
Genetically engineered transfusable platelets using mRNA lipid nanoparticles
Platelet transfusions are essential for managing bleeding and hemostatic dysfunction and could be expanded as a cell therapy due to the multifunctional role of platelets in various diseases. Creating these cell therapies will require modifying transfusable donor platelets to express therapeutic proteins. However, there are currently no appropriate methods for genetically modifying platelets collected from blood donors. Here, we describe an approach using platelet-optimized lipid nanoparticles containing mRNA (mRNA-LNP) to enable exogenous protein expression in human and rat platelets. Within the library of mRNA-LNP tested, exogenous protein expression did not require nor correlate with platelet activation. Transfected platelets retained hemostatic function and accumulated in regions of vascular damage after transfusion into rats with hemorrhagic shock. We expect this technology will expand the therapeutic potential of platelets.
- 1 December 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (48) , eadi0508
Open AccessGenetically engineered transfusable platelets using mRNA lipid nanoparticles
Platelet transfusions are essential for managing bleeding and hemostatic dysfunction and could be expanded as a cell therapy due to the multifunctional role of platelets in various diseases. Creating these cell therapies will require modifying transfusable donor platelets to express therapeutic proteins. However, there are currently no appropriate methods for genetically modifying platelets collected from blood donors. Here, we describe an approach using platelet-optimized lipid nanoparticles containing mRNA (mRNA-LNP) to enable exogenous protein expression in human and rat platelets. Within the library of mRNA-LNP tested, exogenous protein expression did not require nor correlate with platelet activation. Transfected platelets retained hemostatic function and accumulated in regions of vascular damage after transfusion into rats with hemorrhagic shock. We expect this technology will expand the therapeutic potential of platelets.